Raleigh Capital Management Inc. Cytokinetics Inc Transaction History
Raleigh Capital Management Inc.
- $214 Million
- Q1 2025
A detailed history of Raleigh Capital Management Inc. transactions in Cytokinetics Inc stock. As of the latest transaction made, Raleigh Capital Management Inc. holds 13 shares of CYTK stock, worth $536. This represents 0.0% of its overall portfolio holdings.
Number of Shares
13Holding current value
$536% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding CYTK
# of Institutions
402Shares Held
115MCall Options Held
3.46MPut Options Held
1.86M-
Black Rock Inc. New York, NY14.7MShares$606 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA11.9MShares$492 Million0.01% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD10.8MShares$444 Million0.31% of portfolio
-
State Street Corp Boston, MA6.17MShares$255 Million0.01% of portfolio
-
Geode Capital Management, LLC Boston, MA2.84MShares$117 Million0.01% of portfolio
About CYTOKINETICS INC
- Ticker CYTK
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 94,144,096
- Market Cap $3.89B
- Description
- Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates i...